ARTICLE | Company News

TransCelerate pharmaceuticals news

February 2, 2015 8:00 AM UTC

Not-for-profit biopharma consortium TransCelerate added Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) and Novo Nordisk A/S (CSE:NVO; NYSE:NVO, Bagsvaerd, Denmark) as member companies. Last month, Merck completed its acquisition of TransCelerate member Cubist Pharmaceuticals Inc.

The consortium also named as its chairman Briggs Morrison, who is EVP of global medicines development at AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.). He succeeds Annalisa Jenkins, who became chair in February 2014 but stepped down last year after leaving the Merck Serono unit of Merck KGaA (Xetra:MRK, Darmstadt, Germany), another TransCelerate member. ...